Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medco Expects Medicare Discount Card Program To Continue Past 2006

This article was originally published in The Pink Sheet Daily

Executive Summary

"I'll be surprised" if the card program is shut down on schedule, Medco CEO tells analysts. Any extension is good for Medco, he says. PBM is passing on all brand rebates under Medicare card; profits come from enrollment fees and generics.

You may also be interested in...



“U Share” Cuts Mail Order Prices For Pfizer Drugs: Medicare Discount Update

Prices for most other Medicare-endorsed drug discount cards remain stable in the May 24 pricing update. An exception is Omnicare subsidiary PBM Plus, which dropped retail prices $2.25 on many brands, giving it the best price on Crestor and some other products.

Medco Has 600,000 Seniors In Medicare Card Plans; Enrollment Continues

Medco has over 600,000 seniors signed up for its many Medicare-endorsed discount card programs, CEO David Snow told the Banc of America Securities conference in Las Vegas May 20

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS059645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel